The majority of pediatric and younger adult (o60 years) AML patients achieve complete remission. However, 30 --40% of patients relapse and display a dismal outcome. Recently we described a frequent instability of type I/II mutations between diagnosis and relapse. Here, we explored the hypothesis that these mutational shifts originate from clonal selection during treatment/disease progression. Subfractions of blasts from initial diagnosis samples were cell sorted and their mutational profiles were compared with those of the corresponding relapse samples of 7 CD34
INTRODUCTION
Acute myeloid leukemia (AML) is generally regarded a clonal disease in which accumulation of genetic aberrations results in growth of malignant primitive cells from the myeloid blood lineage. 1 With current intensive chemotherapy protocols, complete remission (CR) rates in adult and particularly in pediatric AML patients have greatly improved over the past decades. 2 Nowadays, in most high income countries, 70 --80% of younger adult (o60 years) and over 90% of pediatric AML patients achieve complete remission. 3 However, 30 --40% of patients relapse and face a poor prognosis. 4, 5 It has been proposed that distinct types of molecular aberrations, categorized according to their biological impact (e.g., increase in self renewal, impairment of differentiation, immune evasion and proliferation capacity), act in concert to cause AML. 6 Some of these molecular aberrations, for example FLT3/ITD or t(8;21) are of strong prognostic significance, 7, 8 and also offer opportunities for targeted treatment. 9, 10 It has been shown that cytogenetic alterations can occur between initial diagnosis and relapse. 11 Mutation analyses on the bulk of mononuclear cells by other groups 12, 13 as well as by our own group, 14 --16 revealed that certain molecular aberrations, in particular FLT3/ITD, RAS or WT1, are unstable between initial diagnosis and relapse, whereas the mutational status of other genes (e.g., NPM1) remained constant. 16 --19 Regarding mutational shifts, both gains and losses of mutations occur, except for WT1, in which only an apparent gain of mutations was observed. 16, 20 Moreover, we showed that the mutational shifts in FLT3/ITD, RAS and WT1 are associated with both the time to relapse (TTR) and overall survival. 16 Differences in genetic aberrations between diagnosis and relapse may be explained by: (1) Continuous accumulation of secondary mutations in (pre-) leukemia initiating cells (LICs), (2) Selection and expansion of a minor, initially undetected clone, from an oligoclonal compartment of leukemia initiating cells at the time of initial presentation.
A study by Pollard et al. 21 showed that at diagnosis, particularly the more immature AML cells (determined in their study by CD34 expression and absence of CD33 expression) are heterogeneous in their FLT3/ITD mutational status. Moreover, enrichment for FLT3/ITD-positive cells could be obtained by in vitro exposure to Ara-C. 21 By tracking individual human LICs in non-obese diabeticsevere combined immunodeficient mice serially transplanted with AML cells, Dick and co-workers 22 showed that LICs are not functionally homogeneous as they showed a variable self-renewal capacity. These studies illustrate that LICs from initial diagnosis samples may be heterogeneous in genotype, phenotype and function. Molecular and cytogenetic aberrations may also be associated with expression of particular cell surface markers. 23 Mutational shifts may therefore be accompanied by shifts in immunophenotype between diagnosis and relapse. Conversely, immunophenotype shifts may be a signal that molecular or cytogenetic changes have taken place. Elucidation of molecular and cellular characteristics of primitive populations may offer treatment strategies directed against those cells that cause relapse. 24 Although relapse is the main cause of poor treatment outcome, the underlying molecular mechanisms by which drug-resistant cells cause relapse remain elusive. In the current study we provide evidence for oligoclonality within leukemic subcompartments of initial diagnosis AML samples as defined by CD34/CD38 expression patterns. Mutation analysis of these subfractions indicated the contribution of clonal selection and expansion to the development of relapse in these AML patients.
MATERIALS AND METHODS

Patients and samples
We selected 7 cases from a set of pediatric and adult relapsed AML patients, for which both cell pellets of mononuclear cells (MNCs) and cryo-preserved paired MNC samples from initial diagnosis and relapse were available. Patients were included when, according to mutational profiling of isolated genomic DNA (gDNA) from MNCs, mutational shifts had occurred. Further selection was based on CD34 positivity and the presence of malignant subpopulations in the CD34 þ CD38 À leukemia initiating fraction defined by leukemia associated marker aberrancies. 25 Patients were treated according to the following protocols: MRC AML12, 26 HOVON29, HOVON42(-A). 27 The characteristics of the one pediatric patient and six adult patients are shown in Table 1 .
Isolation of mononuclear cells
Isolation of MNCs was performed as previously described. 28 MNC samples (n ¼ 12) were stored in liquid nitrogen in RPMI-1640 medium (Life Technologies, Paisley, United Kingdom) supplemented with 20% heatinactivated fetal bovine serum (Greiner, Alphen a/d Rijn, The Netherlands) and 10% DMSO (Riedel-de Haen, Seelze, Germany). Prior to analysis, MNCs were thawed and suspended in RPMI-1640 supplemented with 40% fetal bovine serum at 37 1C. Cells were then washed and resuspended in PBS/0.1% BSA. Initial mutation analysis, to screen for mutational shifts between diagnosis and relapse was performed on the bulk of leukemic cells from MNC pellets. To determine mutational status of flow cytometersorted subpopulations, only cryo-preserved cells were used.
Flow cytometry and cell sorting
Leukemia-associated phenotypes (LAPs) on leukemic blasts and aberration markers on cell fractions were determined as previously described, 25 in fresh initial diagnosis samples and at relapse when material was available. Cell sorting strategies were designed to enable characterization of CD34/ CD38 defined sub-populations:
Aberrant marker expression, for example the expression of CD7 (a protein that is normally found on mature T cells but not on myeloid cells) was used to define malignancy in these compartments. CLL-1 was used as an aberrant marker only for the primitive compartments, based on CD38 expression. In specific cases we further used the markers CD133 and CD117. Our sorting strategy is exemplified in Supplementary Figure S1A . When present, differences in marker expression between diagnosis and corresponding relapse samples were used to aid aberrant marker selection (Supplementary Figure S1B) . For cell sorting experiments, cryo-preserved samples were prepared and thawed as previously described. 28 Primary AML cells (1 Â 10 6 /mL) were stained by incubation (15 min at room temperature) with different combinations of fluorescein isothiocyanate (FITC), phycoerythrin (PE), allophycocyanin (APC), peridinin chlorophyll protein-cyanine 5 (PerCP-Cy5), APC-cyanine analogue H7 (APC-H7) and R-phycoerythrin-cyanine 7 (PC7) conjugated monoclonal antibodies (MoAbs). CLL-1 PE was used as previously described 29 and anti-CD45 APC, Anti-CD45 H7, anti-CD38 APC, anti-CD34 PerCP-Cy5, anti-CD34 FITC, anti-CD7 FITC, anti-CD11b PE, anti-CD25 APC and anti-CD133 PE MoAbs were purchased from BD Biosciences (BD Biosciences, San Jose, CA, USA), whereas anti-CD117 PC7 was obtained from Beckman Coulter (Beckman Coulter, Brea, CA, USA). Labeled samples were analyzed using Infinicyt software version 1.5 (Cytognos, Salamanca, Spain) and cells were sorted using a flow cytometer (BD FACSAria, equipped with red, blue, ultra-violet and infrared solid-state lasers and FACSDiva software version 6.1.3; BD Biosciences, San Jose, CA, USA). Prior to molecular analysis, duplicate subfractions were sorted in 96 --well plates in portions of 25 --50 cells.
Mutation profiling
Genomic DNA (gDNA) was isolated from pellets of 5 Â 10 6 MNCs according to the manufacturer's instructions using the Quiagen Allprep kit (Quiagen Benelux B.V., Venlo, The Netherlands). Mutation profiling was performed on isolated gDNA as previously described for FLT3/ITD,(15) NRAS codon 12/13, 30 KRAS exon 1, 31 and NPM1. 16 WT1 exon 7 mutation analysis was performed using previously described primers 20 in a high resolution melting (HRM) curve analysis assay. PCR for HRM analysis was performed on a LightCycler480 (Roche, Mannheim, Germany). The reaction mixtures with a final volume of 10 mL contained: 300 nM forward primer, 300 nM reverse primer and 10 ng genomic DNA in 1 Â Melting curve analysis was performed using LightCycler 480 Software, version 1.5 (Roche, Mannheim, Germany). Direct PCR was applied to cell-sorted subfractions under similar reaction conditions, except for the use of lower reaction volumes (always 10 mL). We used the following cell lines as controls in different assays; MV411 as FLT3/ITD mutated control, THP1 and HL60 as NRAS codon 12/13 mutated and wild type control respectively, HCT116 as a KRAS mutated control, K562 and HL60 as WT1 wild type and positive control (HL60 contains SNP rs16754 in WT1 exon 7), respectively.
Validation of the methods employed in the current study We validated our flow cytometric method in which we combined flow cytometry-based cell sorting of small numbers of AML cells (25 --50 cells), followed by mutation profiling as described above (Supplementary Figure S2) . When a total of 25 cells from the FLT3/ITD-positive MV411 AML cell line and the FLT3/ITD-negative HL60 AML cell line were sorted out at various ratios, we were able to detect 1 --2 FLT3/ITD-positive cells among Abbreviations: INM, insufficient number of metaphases; UPN, unique patient number; WBC, white blood cell count.
Role of Dx BLAST subpopulations in AML relapse C Bachas et al detect 2 cells harboring wild type FLT3 among 23 FLT3/ITD positive cells; wild type versus mutated FLT3 allelic ratio's (ARs) changed in concordance with the ratio of HL60 to MV411 sorted cells. A similar experiment with consistent results was performed by sorting a total of 50 THP-I and HL60 cells in different ratios, followed by NRAS codon 12/13 mutation analysis. Consistently, the ratio of mutant to wild type signal in the mutation analysis associated with the ratio of sorted mutant (THP-I) to wild type (HL60) cells. To test the sensitivity of the WT1 HRM assay, HL60 (SNP rs16754) cells were serially diluted in a background of K562 cells (wild type) to ratios of 10 À1 , 10 À2 , 10
À3
, 10 À4 , 10 À5 and 10 À6 . The cells (5 Â 10 6 ) were sediment by centrifugation and DNA was isolated using DNASTAT-60 (Tel-test Inc., Friendswood, TX, USA) according to manufacturer protocols. Using HRM, SNP rs16754 was detected in dilutions down to 10
À5
.
RESULTS
Characterization of paired diagnosis and relapse samples using standard diagnostics To assess the mutational status of paired initial diagnosis and relapse samples, we isolated gDNA from the bulk of MNCs and determined the mutational status of hotspot regions in 5 genes including FLT3, NRAS, KRAS, WT1 and NPM1. No mutations at either diagnosis or relapse were observed in KRAS and NRAS codon 61. However, shifts were observed for FLT3/ITD, WT1 and NRAS codon 12/13 mutational status. Mutational shifts in the bulk of MNCs are summarized in Table 2 .
Clonality of leukemic subpopulations at AML presentation Mutational shifts between diagnosis and relapse suggest either changes occurring during/after therapy, or selection of minor clones present already at diagnosis. To address the latter possibility, we determined the mutational profiles for the aforementioned genes in purified subfractions of initial samples of each patient. Not all mutations could be determined in the subfractions for all patients, due to limitations in the availability in material from these rare cell subpopulations. Mutation analysis of cell-sorted subfractions was prioritized according to the specific mutations that were found in the gDNA screen of the paired initial diagnosis and relapse samples. In all cases, molecular analysis of duplicate cell-sorted fractions showed a similar result in all samples tested (data not shown). Cell sorted lymphocyte fractions were used as negative controls and showed only wild type alleles in all molecular analyses. In addition to the analyses on the MNCs, the results of the mutation profiling of different subfractions of initial samples are summarized in Table 2 . We cell-sorted minor subpopulations of very low frequencies (as low as 0.002% of the WBC) and analyzed them by direct PCR. The frequencies of these subfractions within the MNC fraction are shown in Supplementary Figure S3 . In general, cell-sorted mature blast fractions (CD45 dim / CD34 þ CD38 þ ) displayed a similar mutational profile when compared to analyses performed on the bulk of MNCs (except for a marginal increase in detection of mutant alleles, data not shown). When the molecular analysis was applied to subfractions of the CD34 þ CD38 dim/À compartment using additional CD133, CD117 and aberrant markers, prominent differences were observed between subfractions in 6 out of the 7 patients. A detailed description of oligoclonality in initial samples of individual patients is given below.
In one out of seven patients (patient 1), no mutational differences were observed between subfractions of the initial diagnosis specimen (Supplementary Figure S3A) . A loss of the wild type FLT3 allele in the whole CD34 þ CD38 À subfractions and aberrant marker positive cells CD117
high within that fraction was observed. The latter was observed in contrast to the CD34 þ CD38 þ fraction and the total blast compartment. All cell-sorted fractions displayed a similar mutation profile for NPM1 and NRAS, with no variation in allelic ratio of mutated genes. In the 6 patients that did show a molecular heterogeneity between the whole blast compartment and isolated subfractions, the molecular markers involved were FLT3/ITD, NRAS and/or WT1. NPM1 mutations were consequently present or absent in isolated subfractions, in concordance with analysis on the bulk of leukemic blast cells. Patient 2 was weakly positive (AR 17%) for an NRAS codon 12/13 mutation at diagnosis according to standard gDNA analysis on the bulk of MNCs. Following cell sorting, this mutant RAS allele was predominantly detected (AR 60%) in CD34 þ CD38 þ cells when compared to the whole blast compartment (Supplementary Figure S3B ). Within the CD34
high cells revealed a homozygous NRAS mutation (AR 100%), whereas the CD133 negative fractions CD117
low fractions both showed a heterozygous presence of the mutated NRAS allele. Hence, this analysis on sorted cells reveals an enrichment of the mutated NRAS allele in a specific (CD34 þ CD38 À CD133 þ CD7 high ) AML subfraction. At diagnosis, all cell-sorted leukemic fractions of patient 2 were FLT3/ITD negative and NPM1 positive, similar to mutational profiles of MNCs.
Patient 3 has a heterogeneous CD34 þ CD38 À compartment according to FLT3/ITD mutation analysis on cell-sorted subfractions (Figure 1a) . Almost all CD34 þ CD38 À CD11b high CD7 low cells showed a homozygous FLT3/ITD mutation (AR 92%), whereas the CD34 þ CD38 À CD11b high CD7 high fraction and blast fractions, such as CD34 þ CD38 þ cells, exhibited a lesser abundance of the mutated allele. The more stable NPM1 mutation, which was Role of Dx BLAST subpopulations in AML relapse C Bachas et al assayed in multiplex on the same sorted cells as FLT3/ITD analysis, remained present in all cell sorted initial fractions. In addition, when we enriched for subfractions within CD34 þ CD38 À cells, a WT1 mutation was detected which was most prominent in the CD34 þ CD38 À CD11b high CD7 low fraction (Figure 1 ). Within the diagnosis sample of patient 4, we evaluated molecular aberrations (Supplementary Figure S3D) of immature subfractions based on differential expression of CD117 and CD7 on the blast fraction (Supplementary Figure S1 ). Molecular analysis of the CD45 dim blast fraction showed a very weak presence of a NRAS codon 12/13 mutated allele and a FLT3/ITD in an allelic ratio of approximately 33%. The more we enriched for subfractions of the CD34 þ CD38 À fraction, the more the allelic presence of the FLT3/ITD was enriched. The CD117 þ CD34 þ CD38 À fraction showed the strongest, virtual homozygous presence of the 75 bp FLT3/ITD mutated allele. The CD117 þ CD34 þ CD38 À CD7 high fraction showed an additional minor 48 bp FLT3/ITD and a moderately increased presence of the mutated NRAS codon 12/13 allele. When compared to this fraction, the CD117 þ CD34 þ CD38 þ fraction showed a lesser abundance of the mutated FLT3/ITD allele, but still higher than the blast fraction. All fractions were NPM1 mutated.
In patient 5 (Supplementary Figure S3E ) the CD45 dim blast fraction showed a strong allelic presence of a mutated NRAS codon 12/13 (AR 81%). In contrast, when analyzing subfractions from the CD34 þ CD38 À fraction, the allelic ratio was lowered within the
À subfraction (AR 7%). Remarkably, all fractions were NPM1 mutated, WT1 and FLT3/ITD negative, except for the total CD34 þ CD38 À fraction and the CD133 À CD117 þ CD34 þ CD38 À fraction, in which a 51 BP FLT3/ITD was detected in a low allelic ratio.
For pediatric AML patient 6 we performed FLT3/ITD and NPM1 mutation analysis on sorted fractions using CD34, CD38 and CLL-1 expression (Supplementary Figure S3F) . All CLL-1 negative fractions were negative for FLT3/ITD, the CD34 þ CD38 À CLL-1 þ fraction harbored a 48 bp FLT3/ITD. This specific FLT3/ITD was also observed within the CD34 þ CD38 dim CLL-1 þ fraction, but this fraction additionally harbored a 21 bp FLT3/ITD at a low allelic ratio (AR 9%) when compared to the wild type allele and the 48 bp FLT3/ITD. From the initial diagnosis material of patient 7 we sorted different sub-fractions using CD117, CD34, CD38 and CD25 (Supplementary Figure S3G) . All leukemic sub-fractions harbored an NPM1 mutation. When compared to the whole CD45 dim blast compartment, the largest sub-compartment of CD117 þ CD34 À cells showed an 18 bp FLT3/ITD mutation in a low allelic ratio. The allelic ratio increased in the CD117 þ CD34 þ compartment, depending on CD38 and CD25 expression. The CD117
high sub-fraction showed the highest allelic ratio (AR 50%).
In summary, we obtained molecular genetic evidence for oligoclonality in 6 out of 7 patients (summarized in Table 2 ), because immature cell sorted subfractions yielded different allelic ratios of NRAS, FLT3/ITD or WT1 mutations.
Selection and expansion of subpopulations from presentation to relapse Striking similarities were observed between mutation profiles of minor subfractions of individual diagnosis samples and the predominant mutation profile of the corresponding relapse sample suggestive for a process of selection in favor of these minor populations after initial treatment. As mentioned above, the initial diagnosis sample of patient 1 showed no signs of clonality according to mutation analyses on subfractions and immunophenotyping. We did not detect any specific clonal expansion since the relapse samples harbored a FLT3/ITD mutation that was not found in any of the initial subpopulations.
For patient 2, a subfraction of the initial sample may have expanded after initial treatment to cause relapse. However, for this patient we were not able to trace back the specific FLT3/ITD mutation that characterizes the relapse sample to a specific subfraction of the diagnosis sample. Therefore the population that dominates at relapse presumably acquired its mutations and expanded during drug therapy: when comparing the mutation Figure 1 . Mutation analysis of the CD34 þ CD38-compartment of patient 3 at diagnosis and relapse. Fragment analyses to assess FLT3/ITDs, NPM1 mutations and normalized difference plots of melting curve temperature shifts to assess WT1 aberrations (bold line represents the sample signal, the grey flat line and grey line represent the negative and positive control respectively). Mutation analyses were performed on 50 leukemic cells of different subfractions at diagnosis (in rows 2 --5) that were sorted from the CD34 þ CD38 À compartment according to the LAPs at diagnosis. Row 1 depicts the CD45dim blasts at relapse and row 6 depicts CD45 dim blasts at diagnosis.
profile of the MNC fraction of the relapse sample of patient 2 (Table 1) with the various mutation profiles of subfractions at diagnosis (Supplementary Figure S3B) , an expansion of cells with unchanged NRAS 12/13 and NPM1 mutation status (mutant) must have occurred, while the bulk of leukemic cells had become FLT3/ITD positive. However, for this patient, we were not able to trace back the origin of the FLT3/ITD mutational shift to a subpopulation in the initial diagnosis sample; hence, compelling evidence for a selection from the NRAS 12/13, NPM1 mutated compartments at diagnosis is lacking. Retaining the NRAS and NPM1 mutation status, while acquiring a FLT3/ITD is suggestive for a clonal evolution. In 5 out of 7 patients we were able to retrace the mutations that predominated at relapse to a minor leukemic subfraction of the initial diagnosis samples. Those mutations were undetectable in the diagnosis sample by standard molecular analyses of the bulk of leukemic cells. In one (patient 3) of these four patients, we observed the selection of a WT1 mutation: the sorted CD34 þ CD38 À CD11b high CD7 low immature subpopulation of the initial sample showed a mutation profile that was identical to that of the relapse sample in terms of FLT3/ITD, NPM1 and WT1 status (mutant) and their allelic ratio (Figure 1) . Together, the molecular data obtained from this patient suggest a selection process which favored the homozygous mutant FLT3/ITD population. In addition, immunophenotyping revealed that this mutation is present in a small malignant sub-population with strong CD11b expression and reduced CD7 expression. This particular population grew out to a full blown blast population at relapse. The alteration in the relative expression of CD11b (from 21.4 to 69.0% of CD34 þ cells) and CD7 (from 67.3 to 16.8% of CD34 þ cells) during disease progression, in the light of the mutational analysis, lends support to the presumption of a positive selection and expansion of a subpopulation of leukemic cells (Figure 2 ).
In the remainder of the patients (i.e., patients 4, 5, 6 and 7) we showed a FLT3/ITD mutation of a specific length that was predominantly present at relapse and could be detected in an immature fraction of the leukemic blasts population in the initial diagnosis sample. Patient 4 gained a 48 bp FLT3/ITD at relapse while the wild type allele was almost completely lost. The 75 bp FLT3/ITD that was already present at diagnosis showed an increase in allelic ratio (Supplementary Figure S3D) at relapse. In patient 5, besides the wild type FLT3 signal, a minor 51 bp FLT3/ITD signal was also detected in the CD34 þ CD38-and CD133
At relapse, a complete shift towards this FLT3/ITD was observed in the whole blast fraction and the wild type allele was completely lost (Supplementary Figure  S3E) . Hence, a selection of FLT3/ITD þ NPM1 þ NRAS À leukemic cells has occurred in this patient. In addition, the immunophenotype data of this patient support a selection and expansion of a minor subpopulation from diagnosis to relapse, as expression of CD133 was lost, whereas aberrant CD7 expression increased (o1 to14%) in CD34 þ CD38 À cells (Supplementary Figure S1B) . In patient 6, the sole 21 bp FLT3/ITD mutation detected at relapse (Figure 3a) was traced back in cells isolated from the CD34 þ CD38 dim fraction. This subpopulation was still heterogeneous since it also harbored the 48 bp FLT3/ITD predominating in the blast cells at diagnosis (Figure 3c ). Patient 7 gained a homozygous 18 bp FLT3/ITD mutation at relapse, while no mutation was observed at initial diagnosis according to standard diagnostics. In addition, immunophenotyping data revealed a strong increase in CD34 and CD25 expression (from 0.4 to 67.3% and 3.7 to 78.1% of WBCs respectively) on leukemic blasts between diagnosis and relapse. All leukemic blasts at either stage of disease expressed CD117. Mutation profiling of sorted fractions from the diagnosis sample showed that the CD117 þ CD34 þ CD38 À CD25 high fraction was NPM1 þ and most enriched for the 18 bp FLT3/ITD (AR 50%) that was homozygously detected in the bulk of leukemic cells at relapse. Taken together, these data suggest an expansion of this immature subpopulation towards relapse.
DISCUSSION
One major strategy to improve the dismal outcome of AML patients is to prevent relapse. Hence, elucidation of the molecular determinants that contribute to the development of relapse is of paramount clinical importance. Studying pediatric and adult AML patients, we have previously shown that shifts in specific type I/ II molecular aberrations occur frequently in between diagnosis and relapse. 15, 16 Here we explored the hypothesis that mutational shifts can be explained by selection and subsequent expansion of leukemic cells from a minor subpopulation of an oligoclonal leukemia-initiating fraction at initial diagnosis, analogous to what has been reported for ALL. 32 We analyzed and compared the mutational profiles of sorted subfractions and proved oligoclonality at initial diagnosis in six out of seven relapsed AML patients. Molecularly heterogenous minor leukemic cell populations were found in these patients in a background of a more uniform blast population. The observed molecular heterogeneity in subpopulations may even be an Figure 2 . Immunophenotyping of the CD34 þ CD38 À and blast compartment of patient 3 at diagnosis and relapse. CD38 expression on CD45 dim CD34 þ cells (primitive compartment) and CD13 expression on 45dim cells (whole blast compartment), both gated from the WBC fraction were gated against an aberrant marker (primitive cells; (a) CD7, (b) CD11b and (c) blasts). A clear change in the relative expression of aberrant markers is observed from predominant CD7 expression at presentation to more prone CD11b expression at relapse. underestimation due to the restricted number of genes that were selected for molecular characterization and the limited availability of aberrant cell surface markers that can discriminate between malignant subfractions. This might also explain the lack of molecular heterogeneity in leukemic subfractions of one of the patients (patient 1). An alternative explanation would be that in this patient the mutation was newly acquired during chemotherapy, hence reflecting a marked genomic instability.
Strikingly, in more than half (5 out of 7) of the AML patients, we were able to trace back the mutational profile, characteristic of the relapse sample, to a minor subpopulation of its corresponding diagnosis sample. These observations in patient material provide a proof of principle to the concept of a selection process in which a pre-existing minor subpopulation from an oligoclonal immature cell compartment at diagnosis, is selected and expanded, thereby causing the relapse.
The molecular profiles were retraceable to a CD34 harbor smaller leukemia initiating subfractions, with a distinct mutation profile, but this remains to be elucidated until proper LSC markers are available for identification of these rare subpopulations.
Using SNP array techniques it was previously shown 39 that uniparental disomy (UPD) occurs frequently in AML patients at diagnosis. 40 Moreover, UPD is often acquired at relapse, which explains changes in gene dosage of e.g. FLT3/ITD mutant alleles between diagnosis and relapse. 41 Our results add to these data by showing that genetic abnormalities, such as UPD, may pre-exist at diagnosis within minor leukemic subpopulations that later expand to cause relapse with manifestation of a changed dosage of mutant alleles.
The sensitivity of PCR-based methods for detection of mutations within mononuclear cell fractions such as HRM or fragment analysis, is typically between 10 À5 and 10 À2 as determined by serial dilution experiments. 42, 43 Prior enrichment of very infrequent subpopulations by fluorescence-activated cell sorting increases the overall sensitivity of PCR-based mutation detection and proved efficient in detecting minor leukemic subpopulations with a specific genotype that emerged at relapse and pre-existed at initial diagnosis of AML, even prior to induction treatment. The latter has several clinical implications: First, risk group stratification could be refined by characterization of genetically heterogeneous subpopulations that may play a role in the development of relapse. Second, detection of molecular aberrations in a small subpopulation of leukemic cells, of which the mutant proteins can directly or indirectly be targeted (e.g., FLT3/ITD or RAS mutations), may render patients eligible for targeted therapy, already at the start of induction therapy. In vitro studies have shown a synergistic mode of action for tyrosine kinase inhibitors with current antileukemic agents, 44 --46 hence a combined targeted approach may prevent the selection and expansion of rare malignant receptor tyrosine kinase mutated sub-populations. Finally, the early detection of minor subpopulations with a distinct mutational profile may justify an alternative approach to MRD assessment. The MRD burden shortly after induction treatment, either assessed by flow cytometry or molecular methods, provides a strong prognostic factor. 47 The present findings may offer an explanation for false negativity in immunophenotypic MRD assessment since a considerable part of patients with low MRD burden nevertheless relapses. 48, 49 In some cases, most notably in patients 3 and 7, genetic alterations were accompanied by alterations in the expression of MRD markers. These changes suggest that immunophenotypic MRD studies cannot always rely on one immunophenotypic aberrancy. 50 However, some of the markers we used are well-established and stable markers for minimal residual disease studies. CD7 for example is expressed in about 25% of diagnosis AML and usually stable during disease. 51 It remains to be established whether changes during disease progression of the expression of markers may reflect clonal changes. For patient 3 it is challenging to hypothesize that the disappearance of CD7 reflects disappearance of the major clone at diagnosis, while increase of CD11b reflects the expansion of the minor clone present at diagnosis. Taking oligoclonality into account, combining flow cytometry and molecular methods as described here and as suggested by others, 52 is likely to improve the applicability and sensitivity of MRD assessment.
In summary, in this unique approach using primary human AML cells we provide molecular evidence that AML harbors an oligoclonal immature compartment at presentation. Moreover, we show for the first time the presence of a minor subpopulation in initial diagnosis AML samples, with a specific mutational profile that later dominated the bulk of leukemic blasts at relapse. Detection of minor subpopulations, with a specific mutational profile, has implications for risk group stratification, accurate MRD assessment as well as the application and timing of targeted treatment. In conclusion, our results underline the concept of oligoclonality in AML and demonstrate a process of selection and expansion of subset chemoresistant leukemic cells in the development of relapse in AML patients.
